Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden (Q51119082)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2008

edit

Language	Label	Description	Also known as
English	Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden	scientific article published in January 2008

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

title

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

main subject

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

follicular lymphoma

1 reference

based on heuristic

inferred from title

rituximab

1 reference

based on heuristic

inferred from title

Sweden

1 reference

based on heuristic

inferred from title

author

Hans Hagberg

series ordinal

3

object named as

Hans Hagberg

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

author name string

Frida Kasteng

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

Martin Erlanson

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

Eva Kimby

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

Thomas Relander

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

Jonas Lundkvist

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

publication date

1 January 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

published in

Acta Oncologica

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

volume

47

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

page(s)

1029-1036

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

cites work

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860802120028

retrieved

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860802120028

retrieved

21 January 2018

Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860802120028

retrieved

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860802120028

retrieved

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1080%2F02841860802120028

retrieved

21 January 2018

Identifiers

DOI

10.1080/02841860802120028

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

PubMed publication ID

18607857

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18607857

retrieved

30 March 2018

reference URL

http://europepmc.org/abstract/MED/18607857

ResearchGate publication ID

5244807

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51119082&oldid=2268206141"